Full-Time

Sr Scientist

PSC Biology

Posted on 9/20/2024

BlueRock Therapeutics

BlueRock Therapeutics

201-500 employees

Develops advanced cellular therapies for diseases

Senior

Cambridge, MA, USA

Position requires onsite presence in Cambridge, Massachusetts.

Category
Computational Biology
Genomics
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • PhD. in Cell Biology, Molecular Biology, Neuroscience, Biomedical Engineering, or related discipline, with 5+ years (B.S. with 14+ years; M.S. with 13+ years) of full-time laboratory experiences in a biological science discipline. Prior full-time laboratory experiences specific to human pluripotent stem cell biology and/or molecular genetics are strongly preferred.
  • Knowledge in several of the following areas: genetics, molecular biology, stem cell biology, cell and developmental biology, regenerative medicine.
  • Hands-on, wet lab experience with molecular biology/genetics techniques (PCR, NGS library prep) is required.
  • Experience with hPSC culture, CRISPR/Cas-based genome engineering and bioinformatic analysis is strongly preferred.
Responsibilities
  • Design and lead diverse NGS sequencing projects (including, but not limited to long-read, short-read genomic sequencing, bulk RNA-seq, scRNA-seq).
  • Analyze and maintain experimental data in electronic laboratory notebooks in a timely and accurate manner.
  • Prepare and follow standard operating procedures, batch records, development and technical reports, and other process documentation.
  • Manage direct report to maintain and characterize hPSC cultures and differentiated progeny.
  • Maintain inventory of required reagents for experiments.
  • Organize and present scientific data to peers through internal and external platforms, including oral presentations, informal discussions, and written communications.
  • Coordinate activities across team members and collaborating teams to ensure project advancement and success.
  • Provide guidance and support to colleagues on the team, leveraging prior experience and scientific expertise.
  • This position requires excellent communication skills, an ability to work independently and collaboratively, and occasional overtime on the weekend and after hours.
BlueRock Therapeutics

BlueRock Therapeutics

View

BlueRock Therapeutics develops advanced cellular therapies using a unique cell gene platform that directs cellular differentiation and genetically engineers cells. This technology allows them to create new types of medicines aimed at treating complex diseases in areas such as neurology, cardiology, and immunology. Their products work by transforming cells to target specific medical conditions, including neurodegenerative diseases, heart failure, and immune disorders. Unlike many competitors, BlueRock focuses on a specialized approach within the rapidly growing field of regenerative medicine, emphasizing strategic partnerships and research and development to advance their therapies. The company's goal is to address challenging medical conditions through innovative cellular treatments and to generate revenue through collaborations, licensing agreements, and eventual commercialization of their therapies.

Company Size

201-500

Company Stage

Acquired

Total Funding

$218.9M

Headquarters

Cambridge, Massachusetts

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA RMAT designation for bemdaneprocel accelerates market entry for Parkinson's therapy.
  • Successful Phase I trial of bemdaneprocel boosts investor confidence and funding potential.
  • Collaboration with bit.bio enhances discovery and development of new cell therapies.

What critics are saying

  • Competition from established firms like Johnson & Johnson may overshadow BlueRock's innovations.
  • Reliance on strategic partnerships poses risks if partners shift focus or resources.
  • Regulatory hurdles could delay product launches, impacting revenue and market position.

What makes BlueRock Therapeutics unique

  • BlueRock uses iPSC technology to create novel cellular therapies for complex diseases.
  • Their strategic partnerships enhance R&D capabilities and expand therapeutic applications.
  • Focus on neurology, cardiology, and immunology addresses challenging medical conditions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

3%
Fujifilm CDI
Sep 3rd, 2024
Fujifilm Congratulates BlueRock Therapeutics for Receiving FDA Clearance of its IND Application for its iPSC-derived Cell Therapy Candidate

OpCT-001 is the first iPSC therapy candidate licensed from the strategic research and development alliance that FUJIFILM Cellular Dynamics, Opsis Therapeutics, and BlueRock Therapeutics entered in 2021 to discover and develop off-the-shelf iPSC-derived cell therapies for ocular diseases.

BioInformant
Jun 12th, 2024
iPSC Applications in Cell Therapy, Drug Discovery, and Beyond

Since May 2021, BlueRock Therapeutics, Fujifilm Cellular Dynamics, and Opsis Therapeutics have had an R&D alliance to develop allogeneic iPSC-derived cell therapies for ocular diseases.

Parkinson's News Today
Jun 3rd, 2024
Cell therapy bemdaneprocel gets FDA RMAT status

The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to bemdaneprocel, a cell therapy BlueRock Therapeutics, a subsidiary of Bayer, is developing to treat Parkinson's disease.

PR Newswire
Aug 28th, 2023
Bluerock'S Phase I Study With Bemdaneprocel In Patients With Parkinson'S Disease Meets Primary Endpoint

Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year.At one-year, exploratory clinical endpoints improved overall, with participants in the high dose cohort showing greater improvement.One year assessment of all participants demonstrated feasibility of transplantation, cell survival, and engraftment.Planning is underway for a Phase II study that is expected to begin enrolling participants in H1 (first half) 2024.BERLIN and CAMBRIDGE, Mass., Aug. 28, 2023 /PRNewswire/ -- Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, announced today details of the positive data from the Phase I clinical trial for bemdaneprocel (BRT-DA01), a stem cell derived investigational therapy for treating Parkinson's disease. The data were presented at the International Congress of Parkinson's Disease and Movement Disorders® in Copenhagen, Denmark.The study met the primary objective of demonstrating safety and tolerability in all 12 participants in the study's low and high dose cohorts, with no serious adverse events (SAEs) reported related to bemdaneprocel through one year. There were two SAEs reported that were unrelated to bemdaneprocel, one seizure attributed to the surgical procedure and one COVID case. Both resolved without sequelae. In addition, 18F-DOPA PET imaging scans demonstrated evidence of cell survival and engraftment in both low and high dose cohorts

Pharmaceutical Technology
Aug 4th, 2023
BlueRock and bit.bio link to develop regulatory T cell-based therapies

BlueRock and bit.bio link to develop regulatory T cell-based therapies.

INACTIVE